Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer
Join David H. Ilson, MD, PhD and Laura H. Tang, MD, PhD from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to gastric cancer.
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of death from cancer in the world. Multidisciplinary team management is essential for the optimal delivery of combined modality treatment for patients with localized gastric cancer. The selection of preoperative and/or postoperative therapy should be based on the stage of the disease, the extent of lymph node dissection, and surgical margins. Improved understanding of the molecular mechanisms of gastric cancers has led to the development of novel therapeutic strategies for advanced or metastatic cancer. In patients with locally advanced or metastatic disease, the decision to offer systemic therapy should be based on the toxicity profile of each drug, patient’s performance status, comorbidities and HER-2 status. Best supportive care for the prevention and management of treatment-related adverse events is always indicated throughout the disease course. It is essential that clinicians use appropriate interventions to relieve major symptoms in order to improve the quality of life and optimize clinical outcomes.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.
David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer
Laura H. Tang, MD, PhD
Memorial Sloan Kettering Cancer
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program. Pending approval, the activity code and approval number will be posted prior to the activity date.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN will be posted prior to the activity date.
- 1.00 CCM clock hours
- 1.00 ACPE contact hours
- 1.00 ANCC contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Following this activity, participants should be able to:
- Review the current standard of care for the management of patients with localized and metastatic gastric cancer.
- Develop an individualized treatment plan incorporating combined modality therapy for patients with locoregional gastric cancer.
- Evaluate the role of targeted therapies for the treatment of locally advanced or metastatic gastric cancer and identify patients who would benefit from these treatment options.